Evidence map›Paper›PMID 31656694›Full record

ArticleBiochemistry & pharmacology : open access2016

Cancer Stem Cell and Gastrointestinal Cancer: Current Status, Targeted Therapy and Future Implications.

Rizwan Ahmad, Punita Dhawan, Amar B Singh

Open access · greenAbstract read
In one paragraph

Article in Biochemistry & pharmacology : open access, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rizwan AhmadDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, USA.
Punita DhawanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, USA.
Amar B SinghDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, USA.
University of Nebraska Medical Center · US

Funding

Role of Claudin-2 in Inflammatory Diseases and Colon CancerR01DK088902 · NIDDK · VANDERBILT UNIVERSITY · PI SINGH, AMAR B · 2011 to 2015
$1.7M
Role of Claudin-1 in Colon CancerI01BX002086 · VA · VETERANS HEALTH ADMINISTRATION · PI DHAWAN, PUNITA · 2013 to 2022
–
BLRD VA I01 BX002086BLRD VA I01 BX002761NIDDK NIH HHS R01 DK088902
6 · The paper itself

Abstract

The cancer stem cells (CSCs) are biologically distinct subset of rare cancer cells with inherent ability of self-renewal, de-differentiation, and capacity to initiate and maintain malignant tumor growth. Studies have further reported that CSCs prime cancer recurrence and therapy resistance. Therefore, targeting CSCs to inhibit cancer progression has become an attractive anti-cancer therapeutical strategy. Recent technical advances have provided a greater appreciation of the multistep nature of the oncogenesis and also clarified that CSC concept is not universally applicable. Irrespective, the role of the CSCs in gastrointestinal (GI) cancers, responsible for the most cancer-associated death, has been widely accepted and appreciated. However, despite the tremendous progress made in the last decade in developing markers to identify CSCs, and assays to assess tumorigenic function of CSCs, it remains an area of active investigation. In current article, we review findings related to the role and identification of CSCs in GI-cancers and discuss the crucial pathways involved in regulating CSCs populations' development and drug resistance, and use of the tumoroid culture to test novel CSCs-targeted cancer therapies.

Indexed as

CarcinogenesisChemoresistanceStem cellTumoroidsWnt-signaling

Identifiers

PMID31656694
PMCPMC6814166
OpenAlexW2345823935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.